A Comparative Essay: The COVID-19 Vaccine Rollout in the UK and the EU

This essay provides a comparative analysis of the COVID-19 vaccine drives in the United Kingdom and the European Union. It begins with an introduction to the COVID-19 vaccine and its purpose. The main body of the essay contrasts the rapid vaccination progress in the UK with the slower rollout in the EU, highlighting the challenges faced by the EU, including issues with vaccine production, side effects, and the lack of financial resources. The essay discusses the advantages of a slower vaccination process, such as allowing for more thorough testing of vaccine efficiency and detection of new variants. It also considers the impact of the delay on public health and the economy. The essay concludes that while the UK has seen a faster vaccination rate, the EU's slower approach has allowed for more comprehensive vaccine testing and the potential to address emerging strains of the virus. The essay references several academic sources to support its arguments, including studies on vaccine effectiveness, risk communication, and antibody escape.

The Vaccine Drive in
UK and in the EU

Contents
INTRODUCTION.......................................................................................................................................3
MAIN BODY..............................................................................................................................................3
CONCLUSION...........................................................................................................................................4
REFERENCES............................................................................................................................................5

INTRODUCTION
The vaccine of Covid-19 is said to be a vaccine which is intended to provide an acquired
immunity against the severe respiratory syndrome coronavirus, a virus which causes corona
disease in the year 2019 (Punzo and et. al., 2020). This essay shall cover one argument against
the vaccine drive in EU and UK.
MAIN BODY
The covid-19 vaccination drive in UK has a strong start wherein the people of UK have
started to receive their vaccination and approximately 4.6 million people have got second dose of
their covid-19 vaccination. EU has the strong pharmaceutical sector but despite this fact, it has a
critical failure stem which hampered its efforts to obtain vaccines partly from institutional set p
of EU and partly from different healthcare practices in EU member states. There has been a
major side effect which the people are facing by taking the covid-19 vaccination that includes
fever, body ache and many other issues. There is a slow production of vaccine which is resulting
in suffering for the people to overcome this health issue. The lack of financial resources is also
one of the reasons for the slower production of vaccines in EU (Focosi and Maggi, 2021).
As vaccine development is a risky process and also it requires expensive human trials
which is affecting the production capacity of vaccines which is also time consuming. But the
vaccination has its advantages which lower the risk of complications in case the body of an
individual is hit by the coronavirus. It is important to get vaccinated and its delay in supplying
the vaccine is also helping the health ministry to address and detect the new variants of the
coronavirus.
It is very essential to have the slower and detailed human trials so that the efficiency if
the vaccine can be determined which will at the end help the people to save their lives from this
harmful disease. The slower process of vaccination in EU is good for the people as it gives extra
time to the pharmaceutical company to test the efficiency of the vaccines. Moreover, the slower
process of vaccination is helping people to understand any of the side effects of the vaccination
so that they can make the decision as to whether they are required to take vaccine or not. This

slower process is also acting as the human trial where the actual people are getting vaccinated
and its efficiency is tested at the ground level.
Lastly, the delay of vaccination is also helping the EU member states to help the avert in
repeating the past pandemic coordination failures in member states on the vaccine development
and the restrictions of pandemic lockdown (Warren and Lofstedt, 2021). Hence, it can be said
that the vaccine drive in EU is benefiting the pharmaceutical companies to detect the early strain
of second wave of covid-19.
CONCLUSION
It is concluded from the above essay that the vaccination drive in UK is fast but taking
the perspective of whole EU member state, the delayed vaccination drive in EU have caused
millions of people to suffer due to harmful strain of second wave of coronavirus. This is
affecting not only people but the economy as a whole due to lockdown. But this delay is also
helping pharmaceutical companies and scientist in taking time to test the efficiency of vaccine.

REFERENCES
Books and Journals
Punzo, O., and et. al., 2020. Influenza vaccine effectiveness studies in Europe: SWOT analysis
of DRIVE collaborating sites. European Journal of Public Health. 30(Supplement_5),
pp.ckaa166-1457.
Focosi, D. and Maggi, F., 2021. Neutralising antibody escape of SARS‐CoV‐2 spike protein:
Risk assessment for antibody‐based Covid‐19 therapeutics and vaccines. Reviews in Medical
Virology.
Warren, G.W. and Lofstedt, R., 2021. COVID-19 vaccine rollout risk communication strategies
in Europe: a rapid response. Journal of Risk Research, pp.1-11.